Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.
IV Maintenance Dosing for the treatment of Early Alzheimer's Disease Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback